Abstract
Importance While systemic inflammation has been implicated in the aetiology of selected neurodegenerative disorders, its role in the development of amyotrophic lateral sclerosis (ALS) is untested.
Objective To quantify the relationship of C-reactive protein (CRP), an acute-phase reactant and marker of systemic inflammation, with ALS occurrence.
Design, Setting, Participants UK Biobank, a prospective cohort study of 502,649 participants who were aged 37 to 73 years when examined at research centres between 2006 and 2010.
Exposure Venous blood was collected at baseline in the full cohort and assayed for CRP. Repeat measurement was made 3-7 years later in a representative subgroup (N=14,514) enabling correction for regression dilution.
Main Outcome(s) and Measure(s) ALS as ascertained via national hospitalisation and mortality registries. We computed multi-variable hazard ratios with accompanying 95% confidence intervals for log-transformed CRP expressed as standard deviation and tertiles.
Results In an analytical sample of 400,884 individuals (218,203 women), a mean follow-up of 12 years gave rise to 231 hospitalisations and 223 deaths ascribed to ALS. After adjustment for covariates which included health behaviours, comorbidity, and socio-economic status, a one standard deviation higher log-CRP was associated with elevated rates of both ALS mortality (hazard ratios; 95% confidence intervals: 1.32; 1.13, 1.53) and hospitalisations (1.20; 1.00, 1.39). There was evidence of dose-response effects across tertiles of CRP for both outcomes (p for trend≤0.05). Correction for regression dilution led to a strengthening of the relationship with CRP for both mortality (1.62; 1.27, 2.08) and hospitalisations (1.37; 1.05, 1.76) ascribed to ALS.
Conclusions and Relevance Higher levels of CRP, a blood-based biomarker widely captured in clinical practice, were associated with a higher subsequent risk of ALS.
Question Is C-reactive protein (CRP), a marker of systemic inflammation widely used in clinical practice, associated with later risk of amyotrophic lateral sclerosis (ALS)?
Findings Following 11 years disease surveillance in 400,884 individuals (218,203 women), after adjustment for covariates and correction for regression dilution, a one standard deviation higher CRP levels were associations with both mortality (hazard ratio; 95% confidence interval: 1.62; 1.27, 2.08) and hospitalisations (1.37; 1.05, 1.76) ascribed to ALS.
Meaning In the present study, CRP has a dose-response relationship with the risk of later ALS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GDB is supported by the US National Institute on Aging (1R56AG052519-01; 1R01AG052519-01A1) and the UK Medical Research Council (MR/P023444/1; MR/X003434/1), and MK by the Wellcome Trust (221854/Z/20/Z), the UK Medical Research Council (MR/S011676/1), the US National Institute on Aging (R01AG056477), and the Academy of Finland (350426). These funders provided no direct financial or material support for the work, and had no role in study design, data collection, data analysis, data interpretation, or report preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the National Health Service National Research Ethics Service with all participants providing written consent. Using pseudonymised data, the present analyses did not require additional permissions.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Access to data: Data from UK Biobank upon application (http://www.ukbiobank.ac.uk/). Part of the present research has been conducted using the UK Biobank Resource under Application 10279.
Funding: GDB is supported by the US National Institute on Aging (1R56AG052519-01; 1R01AG052519-01A1) and the UK Medical Research Council (MR/P023444/1; MR/X003434/1), and MK by the Wellcome Trust (221854/Z/20/Z), the UK Medical Research Council (MR/S011676/1), the US National Institute on Aging (R01AG056477), and the Academy of Finland (350426). These funders provided no direct financial or material support for the work, and had no role in study design, data collection, data analysis, data interpretation, or report preparation.
Email: david.batty{at}ucl.ac.uk
m.kivimaki{at}ucl.ac.uk
philipp.frank.16{at}ucl.ac.uk
crg{at}mrc.soton.ac.uk
liam.wright{at}ucl.ac.uk
Typing error for co-author ('Frank' not 'FRank')
Data Availability
Data from UK Biobank upon application (http://www.ukbiobank.ac.uk/). Part of the present research has been conducted using the UK Biobank Resource under Application 10279.
